H. Farkas

P. Keith, J. Bernstein, R. Schellenberg, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Molecular Dambusters: What Is Behind Hyperpermeability in Bradykinin-Mediated Angioedema?

Z. Nemeth, H. Farkas, L. Cervenak, 2021, Clinical Reviews in Allergy & Immunology.

Secreted Phospholipases A2 in Hereditary Angioedema With C1-Inhibitor Deficiency

F. Granata, G. Marone, G. Lambeau, 2018, Front. Immunol..

Acquired angioedema associated with chronic hepatitis C.

H. Farkas, G. Füst, A. Pár, 1999, The Journal of allergy and clinical immunology.

Angioedema Without Wheals: Challenges in Laboratorial Diagnosis

H. Farkas, D. Csuka, A. Grumach, 2021, Frontiers in Immunology.

Hereditary and acquired angioedema: Problems and progress: Proceedings of the third C1 esterase inhibitor deficiency workshop and beyond

A. Tordai, L. Truedsson, M. López-Trascasa, 2004, Journal of Allergy and Clinical Immunology.

Long-term Safety and Efficacy of Subcutaneous C1-Inhibitor in Older Patients With Hereditary Angioedema.

William H. Yang, J. Bernstein, H. Farkas, 2020, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

[Effect of danazol treatment on growth in pediatric patients with hereditary angioedema due to C1-inhibitor deficiency].

H. Farkas, L. Varga, N. Veszeli, 2017, Orvosi hetilap.

The effect of long-term danazol treatment on haematological parameters in hereditary angioedema

H. Farkas, D. Csuka, É. Imreh, 2016, Orphanet Journal of Rare Diseases.

Pathways of Neutrophil Granulocyte Activation in Hereditary Angioedema with C1 Inhibitor Deficiency

H. Farkas, L. Cervenak, E. Kajdácsi, 2021, Clinical Reviews in Allergy & Immunology.

Hereditary Angioedema: A Family with Several Affected Members

H. Farkas, Z. Chavoshzadeh, S. Darougar, 2019 .

Flow-mediated vasodilation assay indicates no endothelial dysfunction in hereditary angioedema patients with C1-inhibitor deficiency.

H. Farkas, L. Cervenak, I. Karádi, 2019, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Classification, diagnosis, and approach to treatment for angioedema: consensus report from the Hereditary Angioedema International Working Group

M. Triggiani, W. Aberer, J. Bernstein, 2014, Allergy.

Role of Complement in Allergy

H. Farkas, G. Füst, L. Varga, 2004 .

Danazol therapy for hereditary angio-oedema in children

H. Farkas, L. Varga, G. Harmat, 1999, The Lancet.

Proprotein Convertase Is the Highest-Level Activator of the Alternative Complement Pathway in the Blood

P. Gál, P. Závodszky, H. Farkas, 2021, The Journal of Immunology.

Searching for Genetic Biomarkers for Hereditary Angioedema Due to C1-Inhibitor Deficiency (C1-INH-HAE)

Á. Szilágyi, H. Farkas, M. Maurer, 2022, Frontiers in Allergy.

Hereditary angiodema: a current state-of-the-art review, VII: Canadian Hungarian 2007 International Consensus Algorithm for the Diagnosis, Therapy, and Management of Hereditary Angioedema.

William H. Yang, P. Keith, R. Schellenberg, 2008, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Canadian 2003 International Consensus Algorithm For the Diagnosis, Therapy, and Management of Hereditary Angioedema.

William H. Yang, H. Farkas, R. Warrington, 2004, The Journal of allergy and clinical immunology.

Consensus on treatment goals in hereditary angioedema: a global Delphi initiative.

J. Bernstein, W. Lumry, H. Farkas, 2021, The Journal of allergy and clinical immunology.

Endothelial cell activation during edematous attacks of hereditary angioedema types I and II.

H. Farkas, Z. Prohászka, L. Cervenak, 2014, The Journal of allergy and clinical immunology.

Hereditary angioedema attack: what happens to vasoactive mediators?

H. Farkas, M. Bova, M. Galdiero, 2019, International immunopharmacology.

Cleaved kininogen as a biomarker for bradykinin release in hereditary angioedema.

T. Renné, C. Maas, G. Pasterkamp, 2017, The Journal of allergy and clinical immunology.

Icatibant for the treatment of hereditary angioedema with C1-inhibitor deficiency in adolescents and in children aged over 2 years

H. Farkas, K. V. Kőhalmi, 2018, Expert review of clinical immunology.

Pharmacological Management of Hereditary Angioedema with C1-Inhibitor Deficiency in Pediatric Patients

H. Farkas, 2018, Pediatric Drugs.

Icatibant as acute treatment for hereditary angioedema in adults

H. Farkas, 2016, Expert review of clinical pharmacology.

Orphan drugs for the treatment of hereditary angioedema

H. Farkas, 2013 .

Psychometric study of the SF-36v2 in hereditary angioedema due to C1 inhibitor deficiency (C1-INH-HAE)

W. Aberer, R. A. Campos, H. Farkas, 2021, Orphanet Journal of Rare Diseases.

Anti-cholesterol antibody levels in hereditary angioedema

H. Farkas, G. Füst, G. Szeplaki, 2007, Journal of cellular and molecular medicine.

Prophylactic therapy in children with hereditary angioedema.

H. Farkas, G. Füst, D. Csuka, 2013, The Journal of allergy and clinical immunology.

Abstracts of 11th C1-inhibitor Deficiency & Angioedema Workshop

A. Maetzel, H. Farkas, E. Feener, 2019, Allergy, Asthma & Clinical Immunology.

Aspects of hereditary angioedema genotyping in the era of NGS: The case of F12 gene

H. Farkas, M. Bova, M. Magerl, 2018 .

H. Farkas, B. Engel-Yeger, S. Kivity, 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

The importance of complement testing in acquired angioedema related to angiotensin-converting enzyme inhibitors.

H. Farkas, D. Csuka, L. Varga, 2020, The journal of allergy and clinical immunology. In practice.

Atrial natriuretic peptide as a novel biomarker of hereditary angioedema.

H. Farkas, Z. Prohászka, L. Cervenak, 2016, Clinical immunology.

Coincidence of hereditary angioedema (HAE) with Crohn's disease.

H. Farkas, G. Füst, M. Bély, 1999, Immunological investigations.

[Analysis of the relationship between vitamin D3 level and disease severity in hereditary angioedema].

H. Farkas, É. Imreh, L. Varga, 2019, Orvosi hetilap.

[WAO Guideline for the Management of Hereditary Angioedema].

R. Lockey, R. Pawankar, W. Lumry, 2015, Arerugi = [Allergy].

Screening for Plasminogen Mutations in Hereditary Angioedema Patients

H. Farkas, D. Csuka, L. Varga, 2021, Genes.

Less severe clinical manifestations in patients with hereditary angioedema with missense C1INH gene mutations.

A. Tordai, Á. Szilágyi, H. Farkas, 2013, The Journal of allergy and clinical immunology.

Relationship between copy number of genes (C4A, C4B) encoding the fourth component of complement and the clinical course of hereditary angioedema (HAE).

Z. Rónai, H. Farkas, Z. Prohászka, 2007, Molecular Immunology.

Delayed diagnosis of hereditary angioedema with C1‐inhibitor deficiency in iranian children and adolescents

H. Farkas, Z. Pourpak, I. Mohammadzadeh, 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Treatment with C1-inhibitor concentrate does not induce IgM type anti-C1 inhibitor antibodies in patients with hereditary angioedema.

H. Farkas, G. Füst, D. Csuka, 2011, Molecular immunology.

XXIV World Allergy Congress 2015

Dong Hun Lee, Young Han Kim, Byung Soo Kim, 2016, The World Allergy Organization Journal.

Management of upper airway edema caused by hereditary angioedema

H. Farkas, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Association of celiac disease and hereditary angioneurotic edema

A. Tordai, L. Kalmár, H. Farkas, 2002, American Journal of Gastroenterology.

Coexistent systemic mastocytosis and essential thrombocythemia complicated with monoclonal gammopathy and hypocomplementaemia

H. Farkas, J. Csomor, I. Karádi, 2012 .

A novel pathogenetic factor of laryngeal attack in hereditary angioedema? Involvement of protease activated receptor 1

H. Farkas, L. Cervenak, I. Kenessey, 2022, Allergy, Asthma & Clinical Immunology.

Antibody-mediated inhibition of FXIIa blocks downstream bradykinin generation.

Michael J. Wilson, S. Dower, S. Busfield, 2018, The Journal of allergy and clinical immunology.

Erythema Marginatum as an Early Symptom of Hereditary Angioedema: Case Report of 2 Newborns

H. Farkas, I. Martínez-Saguer, 2016, Pediatrics.

The international WAO/EAACI guideline for the management of hereditary angioedema—The 2017 revision and update

R. Lockey, R. Pawankar, W. Lumry, 2018, Allergy.

Pediatric hereditary angioedema due to C1-inhibitor deficiency.

H. Farkas, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

Management of Hereditary Angioedema in Pediatric Patients

H. Farkas, G. Szeplaki, L. Varga, 2007, Pediatrics.

Clinical management of hereditary angio‐oedema in children

H. Farkas, G. Füst, L. Varga, 2002, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Eradication of Helicobacter pylori and improvement of hereditary angioneurotic oedema

H. Farkas, G. Füst, I. Karádi, 2001, The Lancet.

The efficacy of short-term danazol prophylaxis in hereditary angioedema patients undergoing maxillofacial and dental procedures.

H. Farkas, G. Füst, L. Varga, 1999, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

Assessment of inhibitory antibodies in patients with hereditary angioedema treated with plasma-derived C1 inhibitor.

T. Machnig, H. Farkas, J. Edelman, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

“Nuts and Bolts” of Laboratory Evaluation of Angioedema

H. Farkas, L. Cervenak, E. Kajdácsi, 2016, Clinical Reviews in Allergy & Immunology.

Current pharmacotherapy of bradykinin-mediated angioedema

H. Farkas, 2013, Expert opinion on pharmacotherapy.

Acquired Angioedema Associated with Primary Antiphospholipid Syndrome in a Patient with Antithrombin III Deficiency

H. Farkas, G. Füst, G. Szeplaki, 2008, International Archives of Allergy and Immunology.

C1-inhibitor (C1-INH) autoantibodies in hereditary angioedema. Strong correlation with the severity of disease in C1-INH concentrate naïve patients.

H. Farkas, G. Füst, L. Cervenak, 2007, Molecular immunology.

Angioedema due to acquired C1-esterase inhibitor deficiency in a patient with Helicobacter pylori infection.

H. Farkas, G. Füst, L. Varga, 1999, Zeitschrift fur Gastroenterologie.

Esophageal leiomyoma incidentally recognized during an acute attack of hereditary angioneurotic edema.

H. Farkas, G. Füst, L. Varga, 2001, The Journal of allergy and clinical immunology.

Psychometric Field Study of Hereditary Angioedema Quality of Life Questionnaire for Adults: HAE-QoL.

W. Aberer, H. Farkas, E. Remor, 2016, The journal of allergy and clinical immunology. In practice.

HAE international home therapy consensus document

M. Gompels, H. Farkas, M. Levi, 2010, Allergy, asthma, and clinical immunology : official journal of the Canadian Society of Allergy and Clinical Immunology.

The role of the complement system in hereditary angioedema.

H. Farkas, Z. Prohászka, D. Csuka, 2017, Molecular immunology.

Overview of SERPING1 Variations Identified in Hungarian Patients With Hereditary Angioedema

Á. Szilágyi, H. Farkas, D. Csuka, 2022, Frontiers in Allergy.

Hereditary angioedema: molecular and clinical differences among European populations.

A. Tordai, Á. Szilágyi, H. Farkas, 2015, The Journal of allergy and clinical immunology.

HAE-AS: A Specific Disease Activity Scale for Hereditary Angioedema With C1-Inhibitor Deficiency

H. Farkas, P. Staubach, G. Porebski, 2021 .

Hereditary angioedema: a decade of human C1-inhibitor concentrate therapy.

H. Farkas, G. Füst, L. Jakab, 2007, The Journal of allergy and clinical immunology.

International consensus and practical guidelines on the gynecologic and obstetric management of female patients with hereditary angioedema caused by C1 inhibitor deficiency.

Tom Bowen, Erik Waage Nielsen, Hilary Longhurst, 2012, The Journal of allergy and clinical immunology.

The natural history of hereditary angioedema and the impact of treatment with human C1-inhibitor concentrate during pregnancy: a long-term survey.

H. Farkas, G. Füst, F. Tóth, 2010, European journal of obstetrics, gynecology, and reproductive biology.

Disease expression in women with hereditary angioedema.

H. Farkas, C. Bucher, M. Cicardi, 2008, American journal of obstetrics and gynecology.

International consensus on the diagnosis and management of pediatric patients with hereditary angioedema with C1 inhibitor deficiency

M. Triggiani, P. Schmid‐Grendelmeier, W. Aberer, 2016, Allergy.

Diagnosing Pediatric Patients With Hereditary C1-Inhibitor Deficiency—Experience From the Hungarian Angioedema Center of Reference and Excellence

Á. Szilágyi, H. Farkas, D. Csuka, 2022, Frontiers in Allergy.

Clinical characteristics and safety of plasma-derived C1-inhibitor therapy in children and adolescents with hereditary angioedema - a long-term survey.

H. Farkas, L. Varga, N. Veszeli, 2020, The journal of allergy and clinical immunology. In practice.

Investigational drugs in phase I and phase II clinical trials for hereditary angioedema

H. Farkas, M. L. Debreczeni, K. V. Kőhalmi, 2018, Expert opinion on investigational drugs.

Risk of thromboembolism in patients with hereditary angioedema treated with plasma-derived C1-inhibitor.

H. Farkas, Z. Zotter, L. Varga, 2016, Allergy and asthma proceedings.

Management of pregnancies in a hereditary angioedema patient after treatment with attenuated androgens since childhood

H. Farkas, F. Tóth, L. Kőszegi, 2015, Journal of obstetrics and gynaecology : the journal of the Institute of Obstetrics and Gynaecology.

Treatment of attacks with plasma-derived C1-inhibitor concentrate in pediatric hereditary angioedema patients.

H. Farkas, G. Füst, D. Csuka, 2013, The Journal of allergy and clinical immunology.

C1 inhibitors for hereditary angioedema

H. Farkas, L. Varga, 2012 .

Ecallantide is a novel treatment for attacks of hereditary angioedema due to C1 inhibitor deficiency

H. Farkas, L. Varga, 2011, Clinical, cosmetic and investigational dermatology.

rhC1INH: a new drug for the treatment of attacks in hereditary angioedema caused by C1-inhibitor deficiency

H. Farkas, L. Varga, 2011, Expert review of clinical immunology.

Hereditary Angioedema Caused By C1-Esterase Inhibitor Deficiency: A Literature-Based Analysis and Clinical Commentary on Prophylaxis Treatment Strategies

W. Lumry, H. Farkas, P. Busse, 2011, The World Allergy Organization journal.

The effect of long-term danazol prophylaxis on liver function in hereditary angioedema—a longitudinal study

H. Farkas, Z. Prohászka, G. Füst, 2010, European Journal of Clinical Pharmacology.

Treatment of type I and II hereditary angioedema with Rhucin®, a recombinant human C1 inhibitor

H. Farkas, L. Varga, 2008, Expert review of clinical immunology.

Sex hormones in hereditary angioneurotic oedema

H. Farkas, G. Füst, E. Takács, 2004, Clinical endocrinology.

The Hungarian HAE experience.

H. Farkas, L. Varga, 2003, Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis.

Ultrasonography in the diagnosis and monitoring of ascites in acute abdominal attacks of hereditary angioneurotic oedema

H. Farkas, G. Füst, P. Kaposi, 2001, European journal of gastroenterology & hepatology.

Recombinant human C1‐inhibitor in the treatment of acute angioedema attacks

H. Farkas, M. Soeters, J. Nuijens, 2007, Transfusion.

Recombinant human C1 esterase inhibitor treatment for hereditary angioedema attacks in children

H. Farkas, M. Magerl, S. Kivity, 2019, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Treatment Effect and Safety of Icatibant in Pediatric Patients with Hereditary Angioedema.

W. Aberer, J. Bernstein, H. Farkas, 2017, The journal of allergy and clinical immunology. In practice.

Conestat alfa: an orphan drug for the treatment of hereditary angioedema

H. Farkas, 2016 .

Successful prophylaxis with recombinant human C1 inhibitor in a patient with hereditary angioedema.

H. Farkas, Z. Zotter, L. Varga, 2015, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Recombinant human C1-esterase inhibitor relieves symptoms of hereditary angioedema attacks: phase 3, randomized, placebo-controlled trial.

J. Bernstein, W. Lumry, H. Farkas, 2014, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Repeat treatment with icatibant for multiple hereditary angioedema attacks: FAST‐2 open‐label study

P. Schmid‐Grendelmeier, W. Aberer, B. Floccard, 2013, Allergy.

Randomized placebo-controlled trial of the bradykinin B₂ receptor antagonist icatibant for the treatment of acute attacks of hereditary angioedema: the FAST-3 trial.

C. Town, W. Lumry, H. Farkas, 2011, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

HAEdb: A novel interactive, locus‐specific mutation database for the C1 inhibitor gene

A. Tordai, L. Kalmár, H. Farkas, 2005, Human mutation.

Icatibant, a new bradykinin-receptor antagonist, in hereditary angioedema.

William H. Yang, P. Keith, P. Schmid‐Grendelmeier, 2010, The New England journal of medicine.

Patterns of C1-Inhibitor/Plasma Serine Protease Complexes in Healthy Humans and in Hereditary Angioedema Patients

C. Maas, P. Gál, H. Farkas, 2020, Frontiers in Immunology.

Complete kinetic follow‐up of symptoms and complement parameters during a hereditary angioedema attack

H. Farkas, L. Cervenak, E. Kajdácsi, 2018, Allergy.

Prevention of Hereditary Angioedema Attacks with a Subcutaneous C1 Inhibitor

William H. Yang, P. Keith, P. Kralickova, 2017, The New England journal of medicine.

Long‐term efficacy of danazol treatment in hereditary angioedema

H. Farkas, G. Füst, K. Bork, 2011, European journal of clinical investigation.

Adverse effects of danazol prophylaxis on the lipid profiles of patients with hereditary angioedema.

L. Romics, H. Farkas, G. Füst, 2005, The Journal of allergy and clinical immunology.

Short‐term prophylaxis in hereditary angioedema due to deficiency of the C1‐inhibitor – a long‐term survey

H. Farkas, L. Jakab, I. Karádi, 2012, Allergy.

Home treatment of attacks with conestat alfa in hereditary angioedema due to C1-inhibitor deficiency.

H. Farkas, D. Csuka, Z. Zotter, 2014, Allergy and asthma proceedings.

The Global Registry for Hereditary Angioedema due to C1-Inhibitor Deficiency

H. Farkas, L. Bouillet, A. Germenis, 2021, Clinical Reviews in Allergy & Immunology.

Hereditary Angioedema Due to C1-Inhibitor Deficiency – From a Genetic Point of View

Á. Szilágyi, H. Farkas, D. Csuka, 2015 .

Functional C1-inhibitor diagnostics in hereditary angioedema: assay evaluation and recommendations.

H. Joller-jemelka, L. Truedsson, C. Hack, 2008, Journal of immunological methods.

An investigational oral plasma kallikrein inhibitor for on-demand treatment of hereditary angioedema: a two-part, randomised, double-blind, placebo-controlled, crossover phase 2 trial

J. Bernstein, A. Maetzel, W. Lumry, 2023, The Lancet.

Recombinant human C1 esterase inhibitor for hereditary angioedema attacks: A European registry☆

H. Farkas, M. Jesenak, A. Zanichelli, 2021, The World Allergy Organization journal.

Evaluation of the efficacy and safety of home treatment with the recombinant human C1-inhibitor in hereditary angioedema resulting from C1-inhibitor deficiency.

H. Farkas, L. Varga, N. Veszeli, 2020, International immunopharmacology.

Human Plasma-Derived, Nanofiltered, C1-Inhibitor Concentrate (Cinryze®), a Novel Therapeutic Alternative for the Management of Hereditary Angioedema Resulting from C1-Inhibitor Deficiency

H. Farkas, L. Varga, 2012, Biologics in therapy.

Clinical Studies of Recombinant Human C1 Inhibitor (rhC1INH) in Patients with Acute Attacks of Hereditary Angioedema

H. Farkas, J. Nuijens, M. Cicardi, 2008 .

Icatibant for Multiple Hereditary Angioedema Attacks across the Controlled and Open-Label Extension Phases of FAST-3

W. Lumry, H. Farkas, T. Craig, 2015, International Archives of Allergy and Immunology.

Frequency of the virilising effects of attenuated androgens reported by women with hereditary angioedema

H. Farkas, D. Csuka, Z. Zotter, 2014, Orphanet Journal of Rare Diseases.

Parameters of the classical complement pathway predict disease severity in hereditary angioedema.

H. Farkas, G. Füst, D. Csuka, 2011, Clinical immunology.

Baseline level of functional C1-inhibitor correlates with disease severity scores in hereditary angioedema.

H. Farkas, G. Füst, G. Szeplaki, 2010, Clinical immunology.

A review of berotralstat for the treatment of hereditary angioedema

H. Farkas, Zsuzsanna Balla, 2022, Expert review of clinical immunology.

Attenuated androgen discontinuation in patients with hereditary angioedema: a commented case series

H. Farkas, K. Bork, E. Aygören‐Pürsün, 2022, Allergy, Asthma & Clinical Immunology.

Long‐term safety and effectiveness of berotralstat for hereditary angioedema: The open‐label APeX‐S study

H. Iocca, D. Hagin, H. Farkas, 2021, Clinical and translational allergy.

Mitigating Disparity in Health-care Resources Between Countries for Management of Hereditary Angioedema

W. Aberer, W. Lumry, H. Farkas, 2021, Clinical Reviews in Allergy & Immunology.

Long-term efficacy and safety of subcutaneous C1-inhibitor in women with hereditary angioedema: subgroup analysis from an open-label extension of a phase 3 trial

H. Farkas, M. Cicardi, I. Pragst, 2020, Allergy, Asthma & Clinical Immunology.

Oral Plasma Kallikrein Inhibitor for Prophylaxis in Hereditary Angioedema

M. Triggiani, W. Aberer, M. Gompels, 2018, The New England journal of medicine.

University of Southern Denmark Oral plasma kallikrein inhibitor for prophylaxis in hereditary angioedema Aygören-Pürsün,

M. Triggiani, W. Aberer, M. Gompels, 2018 .

Biological therapy in hereditary angioedema: transformation of a rare disease

H. Farkas, H. Longhurst, 2020, Expert opinion on biological therapy.

Thyroid hormones and complement parameters in hereditary angioedema with C1-inhibitor deficiency.

H. Farkas, D. Csuka, É. Imreh, 2016, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

The Expanding Spectrum of Mutations in Hereditary Angioedema.

H. Farkas, K. Bork, B. Zuraw, 2021, The journal of allergy and clinical immunology. In practice.

International consensus on the use of genetics in the management of hereditary angioedema.

S. Cichon, M. Margaglione, Á. Szilágyi, 2020, The journal of allergy and clinical immunology. In practice.

Targeted next-generation sequencing for the molecular diagnosis of hereditary angioedema due to C1-inhibitor deficiency.

M. López-Trascasa, H. Farkas, M. Maurer, 2018, Gene.

Idiopathic Nonhistaminergic Acquired Angioedema Versus Hereditary Angioedema.

H. Farkas, D. Csuka, L. Varga, 2018, The journal of allergy and clinical immunology. In practice.

Mutation screening of the C1 inhibitor gene among Hungarian patients with hereditary angioedema

A. Tordai, L. Kalmár, H. Farkas, 2003, Human mutation.

Successful outcome using C1-inhibitor concentrate in acute pancreatitis caused by hereditary angioedema.

H. Farkas, D. Csuka, L. Varga, 2011, Gastroenterology nursing : the official journal of the Society of Gastroenterology Nurses and Associates.

The relationship between anxiety and quality of life in children with hereditary angioedema

H. Farkas, B. Engel-Yeger, S. Kivity, 2017, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

First report of icatibant treatment in a pregnant patient with hereditary angioedema

H. Farkas, F. Tóth, L. Varga, 2016, The journal of obstetrics and gynaecology research.

Successful pregnancy outcome after treatment with C1-inhibitor concentrate in a patient with hereditary angioedema and a history of four miscarriages.

H. Farkas, F. Tóth, L. Kőszegi, 2012, European journal of obstetrics, gynecology, and reproductive biology.

Continued icatibant use across recurrent attacks in adolescents with hereditary angioedema

W. Aberer, M. Vardi, H. Farkas, 2021, Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology.

Abstracts from the 10th C1-inhibitor deficiency workshop

William H. Yang, A. Szilágyi, M. Margaglione, 2017, Allergy, Asthma & Clinical Immunology.

Diagnosis and Treatment of Bradykinin-Mediated Angioedema: Outcomes from an Angioedema Expert Consensus Meeting

J. Bernstein, H. Farkas, T. Craig, 2014, International Archives of Allergy and Immunology.

Fixed-Dose Subcutaneous C1-Inhibitor Liquid for Prophylactic Treatment of C1-INH-HAE: SAHARA Randomized Study.

William H. Yang, Moshe Y. Vardi, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

The influence of trigger factors on hereditary angioedema due to C1-inhibitor deficiency

H. Farkas, D. Csuka, G. Fust, 2014, Orphanet Journal of Rare Diseases.

Sustained Response Following Acute Treatment Of Hereditary Angioedema Attacks With Recombinant Human C1 Esterase Inhibitor

J. Bernstein, W. Lumry, H. Farkas, 2014 .

Helicobacter pylori infection as a triggering factor of attacks in patients with hereditary angioedema.

H. Farkas, G. Füst, C. Bucher, 2007, Helicobacter.

Angiooedema due to acquired deficiency of C1-esterase inhibitor associated with leucocytoclastic vasculitis.

H. Farkas, G. Füst, M. Bély, 2001, Acta dermato-venereologica.

F12‐46C/T polymorphism as modifier of the clinical phenotype of hereditary angioedema

Á. Szilágyi, H. Farkas, M. Magerl, 2015, Allergy.

A novel assay to diagnose hereditary angioedema utilizing inhibition of bradykinin‐forming enzymes

H. Farkas, A. Kaplan, C. Koch, 2015, Allergy.

Novel duplication in the F12 gene in a patient with recurrent angioedema.

Á. Szilágyi, H. Farkas, Z. Prohászka, 2013, Clinical immunology.

Erythema marginatum preceding an acute oedematous attack of hereditary angioneurotic oedema.

H. Farkas, I. Karádi, L. Varga, 2001, Acta dermato-venereologica.

Side Effects Of Long-Term Treatment With Danazol And Stanozolol In Hereditary Angioedema

H. Farkas, C. Bucher, M. Cicardi, 2007 .

Long term follow-up of complement parameters to improve the management of acquired angioedema due to C1-inhibitor deficiency

H. Farkas, L. Varga, S. Benedek, 2022, Heliyon.

How Angioedema Quality of Life Questionnaire Can Help Physicians in Treating C1-Inhibitor Deficiency Patients?

H. Farkas, L. Varga, K. V. Kőhalmi, 2021, Clinical Reviews in Allergy & Immunology.

A follow‐up survey of patients with acquired angioedema due to C1‐inhibitor deficiency

H. Farkas, L. Varga, S. Benedek, 2020, Journal of internal medicine.

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

W. Lumry, H. Farkas, P. Busse, 2018, BioDrugs.

Lanadelumab for the Prophylactic Treatment of Hereditary Angioedema with C1 Inhibitor Deficiency: A Review of Preclinical and Phase I Studies

W. Lumry, H. Farkas, P. Busse, 2018, BioDrugs.

Long-Term Outcomes with Subcutaneous C1-Inhibitor Replacement Therapy for Prevention of Hereditary Angioedema Attacks.

William H. Yang, P. Keith, J. Bernstein, 2019, The journal of allergy and clinical immunology. In practice.

P. Keith, T. Machnig, J. Bernstein, 2018, The journal of allergy and clinical immunology. In practice.

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS‐2 study

M. Triggiani, J. Bernstein, M. Gompels, 2018, Allergy.

Efficacy and safety of garadacimab, a factor XIIa inhibitor for hereditary angioedema prevention (VANGUARD): a global, multicentre, randomised, double-blind, placebo-controlled, phase 3 trial

William H. Yang, J. Bernstein, W. Lumry, 2023, The Lancet.

Treatment effect of switching from intravenous to subcutaneous C1-inhibitor for prevention of hereditary angioedema attacks: COMPACT subgroup findings.

T. Machnig, J. Bernstein, W. Lumry, 2019, The journal of allergy and clinical immunology. In practice.

Hereditary angioedema: examining the landscape of therapies and preclinical therapeutic targets

H. Farkas, 2019, Expert opinion on therapeutic targets.

Correction to: Long-term health-related quality of life in patients treated with subcutaneous C1-inhibitor replacement therapy for the prevention of hereditary angioedema attacks: findings from the COMPACT open-label extension study

P. Keith, T. Machnig, J. Bernstein, 2021, Orphanet Journal of Rare Diseases.

Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial.

William H. Yang, J. Bernstein, H. Iocca, 2020, The Journal of allergy and clinical immunology.

W. Lumry, H. Farkas, T. Craig, 2017 .

The Levels of the Lectin Pathway Serine Protease MASP-1 and Its Complex Formation with C1 Inhibitor Are Linked to the Severity of Hereditary Angioedema

K. Skjødt, H. Farkas, P. Garred, 2015, The Journal of Immunology.

C1-inhibitor/C1-inhibitor antibody complexes in acquired angioedema due to C1-inhibitor deficiency

H. Farkas, L. Cervenak, E. Kajdácsi, 2023, Orphanet Journal of Rare Diseases.

Neutrophil activation during attacks in patients with hereditary angioedema due to C1-inhibitor deficiency

H. Farkas, M. Józsi, D. Csuka, 2015, Orphanet Journal of Rare Diseases.

Long-term danazol prophylaxis does not lead to increased carotid intima-media thickness in hereditary angioedema patients.

H. Farkas, Z. Prohászka, G. Füst, 2008, Atherosclerosis.

Serum fetuin-A, tumor necrosis factor alpha and C-reactive protein concentrations in patients with hereditary angioedema with C1-inhibitor deficiency

L. Kalabay, H. Farkas, N. Veszeli, 2019, Orphanet Journal of Rare Diseases.

Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1

H. Farkas, Z. Prohászka, L. Cervenak, 2016, Journal of Clinical Immunology.

Endothelial Cell Function in Patients with Hereditary Angioedema: Elevated Soluble E-selectin Level During Inter-attack Periods

H. Farkas, Z. Prohászka, L. Cervenak, 2012, Journal of Clinical Immunology.

Results From FAST-3: A Phase III Randomized, Double-Blind, Placebo-Controlled, Multicenter Study of Subcutaneous Icatibant in Patients with Acute Hereditary Angioedema (HAE) Attacks

W. Lumry, H. Farkas, M. Riedl, 2011 .

Changes of coagulation parameters during erythema marginatum in patients with hereditary angioedema.

H. Farkas, M. Jesenak, L. Varga, 2020, International immunopharmacology.

Diagnosis of hereditary angioedema

H. Farkas, L. Cervenak, K. V. Kőhalmi, 2018 .

The European Register of Hereditary Angioedema: Experience and Preliminary Results

R. Perricone, H. Farkas, C. Bucher, 2007 .

Acute abdominal attack of hereditary angioneurotic oedema associated with ultrasound abnormalities suggestive of acute hepatitis

H. Farkas, I. Karádi, L. Varga, 2002, Acta paediatrica.

A novel deep intronic SERPING1 variant as a cause of hereditary angioedema due to C1-inhibitor deficiency.

H. Farkas, M. Maurer, M. Magerl, 2020, Allergology international : official journal of the Japanese Society of Allergology.

C1-inhibitor autoantibodies in SLE

T. Mészáros, L. Czirják, H. Farkas, 2010, Lupus.

Deciphering the Genetics of Primary Angioedema with Normal Levels of C1 Inhibitor

H. Farkas, M. Bova, S. D. Del Giacco, 2020, Journal of clinical medicine.

Estrogen-independent hereditary angioedema with normal C1 inhibitor function in a 10-year-old boy.

H. Farkas, P. Eigenmann, C. Drouet, 2013, Annals of allergy, asthma & immunology : official publication of the American College of Allergy, Asthma, & Immunology.

The characteristics of upper airway edema in hereditary and acquired angioedema with C1‐inhibitor deficiency

H. Farkas, D. Csuka, L. Varga, 2021, Clinical and translational allergy.

This information is current as the Severity of Hereditary Angioedema Formation with C 1 Inhibitor Are Linked to Protease MASP-1 and Its Complex The Levels of the Lectin Pathway Serine

K. Skjødt, H. Farkas, P. Garred, 2015 .

Definition, aims, and implementation of GA2LEN/HAEi Angioedema Centers of Reference and Excellence

Todor A Popov, T. Zuberbier, N. Papadopoulos, 2020, Allergy.

Strong correlation of high EBNA-1-IgG levels with edematous attacks involving upper airway mucosa in hereditary angioedema due to C1-inhibitor deficiency.

H. Farkas, G. Füst, D. Csuka, 2012, Molecular immunology.

Safety Of Plasma-derived C1-inhibitor Treatment In Pediatric Patients With Hereditary Angioedema Due To C1-inhibitor Deficiency – A Long-term Survey

H. Farkas, L. Varga, N. Veszeli, 2017 .

Home treatment of hereditary angioedema with icatibant administered by health care professionals.

H. Farkas, L. Jakab, D. Csuka, 2012, The Journal of allergy and clinical immunology.

Oral Plasma Kallikrein Inhibitor BCX7353 is Safe and Effective as an On‐Demand Treatment of Angioedema Attacks in Hereditary Angioedema (HAE) Patients: Results of the ZENITH‐1 Trial: 110

W. Aberer, D. Hagin, S. Faust, 2019, Journal of Allergy and Clinical Immunology.

Abdominal symptoms of hereditary angioedema and early weaning

H. Farkas, G. Füst, I. Czaller, 2010, European Journal of Clinical Nutrition.

Risk for Attacks in Hereditary Angioedema (HAE) Population Correlates with C1-inhibitor Functional Activity (C1-INHact)

J. Bernstein, H. Farkas, M. Cicardi, 2017 .

A novel prophylaxis with C1-inhibitor concentrate in hereditary angioedema during erythema marginatum.

H. Farkas, L. Cervenak, L. Varga, 2017, Immunology letters.

Helicobacter pylori Infection as a Triggering Factor of Attacks in Patients with Hereditary Angioedema

H. Farkas, G. Füst, C. Bucher, 2007 .

Laryngeal angioedema caused by a rare disease—A case report

H. Farkas, E. Kajdácsi, S. Benedek, 2022, Current Problems in Cancer: Case Reports.

Association of celiac disease and hereditary angioneurotic edema.

A. Tordai, L. Kalmár, H. Farkas, 2002 .

Association of celiac disease and hereditary angioedema due to C1-inhibitor deficiency. Screening patients with hereditary angioedema for celiac disease: is it worth the effort?

H. Farkas, G. Füst, Z. Szabó, 2011, European journal of gastroenterology & hepatology.

[Efficacy of short-term danazol treatment in hereditary angioneurotic edema patients undergoing maxillofacial and dental surgical procedures].

H. Farkas, G. Füst, L. Varga, 1998, Fogorvosi szemle.

Activation of the ficolin-lectin pathway during attacks of hereditary angioedema.

H. Farkas, Z. Prohászka, P. Garred, 2014, The Journal of allergy and clinical immunology.

Activation of the ficolin-lectin pathway during attacks of hereditary angioedema

H. Farkas, Z. Prohászka, P. Garred, 2013 .

An abdominal attack of hereditary angio-oedema

H. Farkas, D. Csuka, 2013, The Lancet.

Deep Intronic SERPING1 Gene Variants: Ending One Odyssey and Starting Another?

H. Farkas, A. Germenis, D. Csuka, 2020, Journal of clinical immunology.

Genetic Determinants of C1 Inhibitor Deficiency Angioedema Age of Onset

H. Farkas, M. Maurer, M. Magerl, 2017, International Archives of Allergy and Immunology.

Bacteriuria increases the risk of edematous attacks in hereditary angioedema with C1‐inhibitor deficiency

H. Farkas, É. Imreh, Z. Zotter, 2016, Allergy.

University of Southern Denmark International Consensus on the Use of Genetics in the Management of Hereditary Angioedema Germenis,

S. Cichon, M. Margaglione, H. Farkas, 2020 .

Care of patients with inborn errors of immunity in thirty J Project countries between 2004 and 2021

J. Casanova, A. Šedivá, Y. Rodina, 2022, Frontiers in Immunology.

Differentiating histaminergic and nonhistaminergic angioedema with or without urticaria.

H. Farkas, M. Riedl, Zsuzsanna Balla, 2022, The Journal of allergy and clinical immunology.

High Normal Serum Levels of C3 and C1 Inhibitor, Two Acute-Phase Proteins Belonging to the Complement System, Occur More Frequently in Patients with Crohn's Disease Than Ulcerative Colitis

M. Daha, H. Farkas, Z. Prohászka, 2003, Digestive Diseases and Sciences.

Hereditary angioedema C1-esterase inhibitor replacement therapy and coexisting autoimmune disorders: findings from a claims database

H. Farkas, D. Supina, M. Fridman, 2020, Allergy, Asthma & Clinical Immunology.

Depressed activation of the lectin pathway of complement in hereditary angioedema

P. Gál, H. Farkas, G. Füst, 2008, Clinical and experimental immunology.

Acquired Angioedema Due to C1 inhibitor Deficiency Caused by Non-Hodgkin Lymphoma in a Patient with Myasthenia Gravis

H. Farkas, V. Nădăşan, L. Varga, 2021, Romanian Journal of Laboratory Medicine.

National survey on clinical and genetic characteristics of patients with hereditary angioedema in Latvia

H. Farkas, L. Gailīte, N. Kurjane, 2023, Allergy, Asthma & Clinical Immunology.

C1 inhibitor deficiency enhances contact pathway mediated activation of coagulation and venous thrombosis.

J. Hansen, N. Mackman, K. McCrae, 2023, Blood.

A safety review of prophylaxis drugs for adolescent patients with hereditary angioedema

H. Farkas, Zsuzsanna Balla, 2023, Expert opinion on drug safety.

Novel Vasoregulatory Aspects of Hereditary Angioedema: the Role of Arginine Vasopressin, Adrenomedullin and Endothelin-1

H. Farkas, Z. Prohászka, L. Cervenak, 2016, Journal of Clinical Immunology.

Glucocorticoid receptor gene polymorphisms in hereditary angioedema with C1-inhibitor deficiency

A. Patócs, H. Farkas, Z. Nagy, 2017, Orphanet Journal of Rare Diseases.

Deep Intronic SERPING1 Gene Variants: Ending One Odyssey and Starting Another?

H. Farkas, A. Germenis, D. Csuka, 2020, Journal of Clinical Immunology.

ALLERGY, ASTHMA & CLINICAL IMMUNOLOGY REVIEW Open Access

P. Keith, J. Bernstein, R. Schellenberg, 2022 .

Evidence‐based recommendations for the therapeutic management of angioedema owing to hereditary C1 inhibitor deficiency: consensus report of an International Working Group

M. Triggiani, W. Aberer, R. Perricone, 2012, Allergy.

Evaluation of avoralstat, an oral kallikrein inhibitor, in a Phase 3 hereditary angioedema prophylaxis trial: The OPuS-2 study

H. Farkas, L. Bouillet, J. Bernstein, 2019 .

Deep venous thrombosis associated with acquired angioedema type II in a patient heterozygous for the mutation of factor V Leiden: Effective treatment and follow-up for four years

H. Farkas, G. Füst, I. Karádi, 2006, Thrombosis and Haemostasis.